| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df3db7dfdc978c1cc3f2ba7cc0aee7a4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-737
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-737 |
| filingDate |
2017-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd3b37a90bde39c9d3d5d8ce6ba5fc85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da6bd83f7a60f59724f4f9d79e0cdd8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7a000546da95253877db59521be3faa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f454f28f61600376855fcc984f49e84d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60b906141523199b29518cd3c8160d42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b8806c3badd2686d27b6ab2151e67a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34f0ca9a07921aa2c0a153d5194b6afe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b33d5c5fb45ac47778ddd3304b970cdc |
| publicationDate |
2019-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019343870-A1 |
| titleOfInvention |
Application of alginic acid sulfate in preparation of drugs and health care products for preventing and treating diseases caused by human papilloma viruses |
| abstract |
An application of alginate sulfate in the preparation of drugs and health care products for preventing and treating diseases caused by human papillomavirus. Alginate sulfate has a strong dose-dependent inhibitory effect on HPV infection through experiments, and alginate sulfate inhibited the expression of E6 and E7 genes and proteins in HPV-transformed Hela and Caski cells in a dose-dependent manner. The alginate sulfate can be developed into a drug or a health care product against human papillomavirus by systematic scientific experiments, which will have a good market application prospect. |
| priorityDate |
2016-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |